SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Pediatric Oncology Nursing
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Kassner, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kassner, E.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Evaluation and Treatment of Chemotherapy Extravasation Injuries

Elizabeth Kassner, MS, RN, CPNP, CPON

Extravasation of chemotherapeutic vesicant agents can result in significant tissue damage, alteration in limb function, and pain. Quality of life for long-term survivors can be severely impacted by negative sequelae from vesicant extrava sation. Currently, there is no known preventive therapy. Early detection and intervention are paramount to halt tissue damage and reduce the chance of permanent disability or disfigurement. This article provides an overview of known chemotherapeutic vesicants (mechlorethamine, mitomycin-C, doxorubi cin, daunomycin, vincristine and vinblastine), associated theories of tissue destruction, assessment techniques for peripheral intravenous sites, vascular access devices and central venous lines, current treatment strategies, and investigational therapies. A brief discussion of the legal implications of extrava sation injuries and recommended key points for medical record documentation are included.

Journal of Pediatric Oncology Nursing, Vol. 17, No. 3, 135-148 (2000)
DOI: 10.1053/jpon.2000.8063
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 CA Cancer J ClinHome page
M. Gallieni, M. Pittiruti, and R. Biffi
Vascular Access in Oncology Patients
CA Cancer J Clin, November 1, 2008; 58(6): 323 - 346.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
D. Reeves
Management of Anthracycline Extravasation Injuries
Ann. Pharmacother., July 1, 2007; 41(7): 1238 - 1242.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
P. J Gilbar and C. V Carrington
The incidence of extravasation of vinca alkaloids supplied in syringes or mini-bags
Journal of Oncology Pharmacy Practice, June 1, 2006; 12(2): 113 - 118.
[Abstract] [PDF]

Home page
 Journal of Pediatric Oncology NursingHome page
M. C. Hooke
Clinical Nurse Specialist and Evidence-Based Practice: Managing Anthracycline Extravasation
Journal of Pediatric Oncology Nursing, September 1, 2005; 22(5): 261 - 264.
[Abstract] [PDF]


Advertisement